Tarlatamab: Invaluable Time for Patients With Extensive-Stage Small Cell Lung Cancer.

IF 0.9 4区医学 Q3 NURSING

Clinical journal of oncology nursing Pub Date : 2026-09-30 DOI:10.1188/26.CJON.347-351

Elizabeth Jane Entrop, Casey B Brown

引用次数: 0

Abstract

Extensive-stage small cell lung cancer (ES-SCLC) remains highly aggressive and has a poor prognosis. Tarlatamab-dlle (tarlatamab), a bispecific T-cell engager targeting delta-like ligand 3, offers a novel therapeutic option f.

查看原文本刊更多论文

塔拉他单抗：广泛期小细胞肺癌患者的宝贵时间。

广泛期小细胞肺癌（ES-SCLC）仍然具有高度侵袭性，预后较差。tarlatamab -dlle （tarlatamab）是一种靶向δ样配体3的双特异性t细胞参与剂，提供了一种新的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical journal of oncology nursing ONCOLOGY-NURSING

CiteScore

1.70

自引率

9.10%

发文量

127

审稿时长

6-12 weeks

期刊介绍： The Clinical Journal of Oncology Nursing (CJON) is an official publication of the Oncology Nursing Society (ONS) and is directed to the practicing nurse specializing in the care of patients with an actual or potential diagnosis of cancer. CJON is a vehicle to promote the mission of ONS, which is to advance excellence in oncology nursing and quality cancer care. The CJON mission is twofold: to provide practical information necessary to care for patients and their families across the cancer continuum and to develop publication skills in oncology nurses.